Yükleniyor... / Loading...
Treatment of B-Chronic Lymphocytic Leukemia (B-CLL) With Autologous CD40 Ligand and IL-2-Expressing Tumor Cells
Bu çalışma, B hücreli kronik lenfositik lösemi (B-cell chronic lymphocytic leukemia, B-CLL) hastalığında, hastanın kendi tümör hücrelerinden hazırlanan ve CD40 ligand ile IL-2 üreten bir aşı tedavisini incelemektedir. Çalışmaya, ölçülebilir hastalığı olan B-CLL hastaları katılabilmiştir. Baylor College of Medicine tarafından yürütülen çalışma Faz 1 aşamasında yürütülmüş ve tamamlanmıştır.
Yukarıdaki özet, resmî kaydın sade dile aktarılmış halidir. Orijinal İngilizce başlık referans için gösterilir.
Kriterler ClinicalTrials.gov kaydından orijinal İngilizce haliyle alınmıştır. Uygunluk kararını yalnızca deneyi yürüten ekip verebilir.
INCLUSION CRITERIA: Eligibility for blast collection: * Patients are eligible for administration of their vaccine if they present with B-CLL (not in Richter's transformation) with measurable disease. * Procurement consent signed and faxed to Research Coordinator * Eligibility for Vaccine Administration (protocol entry) * Manipulated B-CLL cells available (at least 12 injections) * Patients are eligible for administration of their vaccine if they present with B-CLL (not in Richter's transformation) with measurable disease * Patients must have a life expectancy of at least 10 weeks. * Patients must have ECOG performance status of 0-2 as below: * Grade 0: Up and about, no restriction * Grade 1: Ambulatory, no strenuous activity * Grade 2: Ambulatory, capable of self-care appropriate for age. Up and about \> 50% of time, but unable to carry out any physical activities or attend school. * Grade 3: Limited self-care only. Up and about \< 50% of time * Grade 4: Disabled, no self-care. Bedridden or confined to chair * Patients must have recovered from the toxic effects of all prior chemotherapy before entering this study, and must have an absolute neutrophil count (ANC) of greater than or equal to 500/uL, absolute lymphocyte count (ALC) greater than or equal to 200/uL, hemoglobin greater than or equal to 8 g/dL and platelet count greater than or equal to 50,000/uL. * Patients must be willing to practice appropriate birth control methods during the study and for 3 months after the study is concluded. This includes total abstinence, oral contraceptives, an intrauterine device, contraceptive implants under the skin, contraceptive injections (Depo-Provera \[Registered\]). Contraceptive foam with a condom is allowed. The male partner should use a condom. * Patients must have adequate liver function (total bilirubin less than or equal to 1.5 mg/dl, SGOT less than or equal to 3 times normal, normal prothrombin time). * Patients must have adequate renal function (creatinine less than 3 times normal for age or creatinine clearance greater than 80 mg/min/1.73m\^2). * Patients must sign an informed consent indicating that they are aware this is a research study and have been told of its possible benefits and toxic side-effects. Patients will be given a copy of the consent form. * Patient must not have received treatment with other investigational agents within the last 4 weeks. EXCLUSION CRITERIA: * Infected at time of protocol entry, or receiving antibiotics (other than prophylactic trimethoprim sulfamethoxazole). * HIV positive * Pregnant or lactating * Suffering from an autoimmune disease (including active graft-versus-host disease-GvHD, refractory immune thrombocytopenia-ITP or refractory autoimmune hemolytic anemia-AIHA) * Receiving immunosuppressive drugs * Patients without adequate cardiac function (congestive heart failure, significant arrhythmia)